当前位置: X-MOL 学术Eur. J. Histochem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
European Journal of Histochemistry ( IF 2 ) Pub Date : 2021-01-20 , DOI: 10.4081/ejh.2021.3173
Zhi Chen 1 , Na Cui 2 , Ji-Sen Zhao 3 , Jian-Fei Wu 3 , Fang Ma 3 , Cong Li 3 , Xian-Yi Liu 4
Affiliation  

As the leading malignancy among women, breast cancer is a serious threat to the life and health of women. In this context, it is of particular importance that a proper therapeutic target be identified for breast cancer treatment. We collected the pathological tissues of 80 patients, with the view to discovering appropriate molecular targets for the treatment of breast cancer, this paper analyzes the expressions of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer tissues, as well as their correlations with breast cancer in combination with the clinicopathologic characteristics of studied patients. Immunohistochemistry (IHC) was utilized to detect the expression levels of ZNF436, β-catenin, EGFR and CMTM5 in cancerous and paracancerous tissues of breast cancer patients. The expression levels of ZNF436, β-Catenin and EGFR in breast cancer tissues were significantly greater than those in paracancerous tissues in this study (p<0.05), while CMTM5 was highly expressed in paracancerous tissues (p<0.05). Additionally, the correlation of the expressions of such indicators with the staging, differentiation and lymphatic metastasis of breast cancer, were also found to be statistically significant at the level p<0.05. The different expression levels of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer and paracancerous tissues open up the possibility of utilizing them as molecular markers for breast cancer. These findings provide a theoretical basis for targeted molecular therapies for breast cancer, and hence carry a significant practical significance.



中文翻译:

ZNF436、β-catenin、EGFR、CMTM5在乳腺癌中的表达及其临床意义

乳腺癌作为女性的首要恶性肿瘤,严重威胁着女性的生命和健康。在这种情况下,为乳腺癌治疗确定合适的治疗靶点尤为重要。我们收集了 80 例患者的病理组织,以期发现治疗乳腺癌的合适分子靶点,本文分析了 ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌组织中的表达,以及它们与乳腺癌组织的相关性。乳腺癌与研究患者的临床病理特征相结合。利用免疫组织化学(IHC)检测乳腺癌患者癌组织和癌旁组织中ZNF436、β-catenin、EGFR和CMTM5的表达水平。ZNF436 的表达水平,本研究中乳腺癌组织中β-Catenin和EGFR的表达显着高于癌旁组织(p<0.05),而CMTM5在癌旁组织中高表达(p<0.05)。此外,还发现这些指标的表达与乳腺癌的分期、分化和淋巴转移的相关性在p<0.05的水平上具有统计学意义。ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌和癌旁组织中的不同表达水平开辟了利用它们作为乳腺癌分子标志物的可能性。这些发现为乳腺癌靶向分子治疗提供了理论基础,具有重要的现实意义。而CMTM5在癌旁组织中高表达(p<0.05)。此外,还发现这些指标的表达与乳腺癌的分期、分化和淋巴转移的相关性在p<0.05的水平上具有统计学意义。ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌和癌旁组织中的不同表达水平开辟了利用它们作为乳腺癌分子标志物的可能性。这些发现为乳腺癌靶向分子治疗提供了理论基础,具有重要的现实意义。而CMTM5在癌旁组织中高表达(p<0.05)。此外,还发现这些指标的表达与乳腺癌的分期、分化和淋巴转移的相关性在p<0.05的水平上具有统计学意义。ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌和癌旁组织中的不同表达水平开辟了利用它们作为乳腺癌分子标志物的可能性。这些发现为乳腺癌靶向分子治疗提供了理论基础,具有重要的现实意义。还发现在 p<0.05 的水平上具有统计学显着性。ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌和癌旁组织中的不同表达水平开辟了利用它们作为乳腺癌分子标志物的可能性。这些发现为乳腺癌靶向分子治疗提供了理论基础,具有重要的现实意义。还发现在 p<0.05 的水平上具有统计学显着性。ZNF436、β-catenin、EGFR 和 CMTM5 在乳腺癌和癌旁组织中的不同表达水平开辟了利用它们作为乳腺癌分子标志物的可能性。这些发现为乳腺癌靶向分子治疗提供了理论基础,具有重要的现实意义。

更新日期:2021-01-20
down
wechat
bug